https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/CODX/co-diagnostics-global-health-roundtable-ebola BiopharmaWatch en 2026-09-21T13:00:00.000Z Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation https://www.biopharmawatch.com/news/PALI/palisade-bio-stifel-2026-forum-presentation BiopharmaWatch en 2026-09-21T13:00:00.000Z Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-menarini-approval-ubicetrapib BiopharmaWatch en 2026-09-21T13:00:00.000Z NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) https://www.biopharmawatch.com/news/NSPR/inspiremd-amendments-series-j-k-warrants-fda-approval BiopharmaWatch en 2026-09-21T13:00:00.000Z InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million https://www.biopharmawatch.com/news/HYFT/mindwalk-openfold3-production-amd-vultr BiopharmaWatch en 2026-09-21T12:46:00.000Z MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-granted-first-australian-patent-breast-cancer-vaccine-broadening BiopharmaWatch en 2026-09-21T12:45:00.000Z Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 https://www.biopharmawatch.com/news/NAGE/cd38-driver-nad-decline-nicotine-riboside-pregnancy-outcomes BiopharmaWatch en 2026-09-21T12:32:00.000Z Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes https://www.biopharmawatch.com/news/BEAT/heartbeam-letter-to-shareholders BiopharmaWatch en 2026-09-21T12:31:00.000Z HeartBeam, Inc. Letter to Shareholders https://www.biopharmawatch.com/news/CLNN/clene-closes-4-million-offering-fda-decision-cnm-au8 BiopharmaWatch en 2026-09-21T12:30:00.000Z Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA https://www.biopharmawatch.com/news/DGX/lyme-disease-co-positive-tick-pathogens-study BiopharmaWatch en 2026-09-21T12:03:00.000Z Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics https://www.biopharmawatch.com/news/LABT/lakewood-amedev-biotherapeutics-nu-3-progress-outlook BiopharmaWatch en 2026-09-21T12:02:00.000Z Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 https://www.biopharmawatch.com/news/A/agilent-tapestationdx-systems-launch-clinical-ngs BiopharmaWatch en 2026-09-21T12:00:00.000Z Agilent Launches TapeStationDx Systems for Clinical NGS Sample Quality Control https://www.biopharmawatch.com/news/ESTA/establishment-labs-breast-tissue-preservation-data BiopharmaWatch en 2026-09-21T12:00:00.000Z Establishment Labs® Highlights New Breast Tissue Preservation Data and Announces Minimally Invasive Product Extensions at the 11th World Symposium on Ergonomic Implants https://www.biopharmawatch.com/news/ABBV/abbvie-iambic-collaboration-ai-drug-discovery BiopharmaWatch en 2026-09-21T12:00:00.000Z AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery https://www.biopharmawatch.com/news/IMMP/change-american-depositary-share-ratio-immp BiopharmaWatch en 2026-09-21T12:00:00.000Z Change to American Depositary Share Ratio https://www.biopharmawatch.com/news/NTHI/neonc-nasal-route-brain-cancer-treatment BiopharmaWatch en 2026-09-21T12:00:00.000Z NeOnc Charting New Nasal Route to Treating Brain Cancer https://www.biopharmawatch.com/news/HELP/helus-pharma-hlp003-mdd-psych-congress-2026 BiopharmaWatch en 2026-09-21T11:30:28.000Z Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 https://www.biopharmawatch.com/news/USPH/us-physical-therapy-new-board-member-myra-davis BiopharmaWatch en 2026-09-21T11:30:00.000Z U.S. Physical Therapy Announces the Appointment of New Board Member Myra Davis https://www.biopharmawatch.com/news/IFRX/inflarx-virtual-capital-markets-event-november-2026 BiopharmaWatch en 2026-09-21T11:30:00.000Z InflaRx to Host Virtual Capital Markets Day https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-gorlin-syndrome-development-focus BiopharmaWatch en 2026-09-21T11:30:00.000Z Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment https://www.biopharmawatch.com/news/TLSA/tiziana-phase-2a-inform-ms-trial-completion BiopharmaWatch en 2026-09-21T11:00:00.000Z Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab https://www.biopharmawatch.com/news/BRKR/bruker-nmr-systems-upgrade-uc-berkeley BiopharmaWatch en 2026-09-21T11:00:00.000Z Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley https://www.biopharmawatch.com/news/NAIA/naia-launch-247-mind-mentor-felix-global-partnership BiopharmaWatch en 2026-09-21T11:00:00.000Z naia Relief Inc. Announces Launch of naia 24/7 Mind Mentor Through Strategic Partnership with Felix Global https://www.biopharmawatch.com/news/ALKS/alkermes-phase-1b-results-alks-7290-adhd BiopharmaWatch en 2026-09-21T11:00:00.000Z Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-isssi-2026-genetic-diversity-ap-sa02 BiopharmaWatch en 2026-09-21T11:00:00.000Z Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates https://www.biopharmawatch.com/news/SCNI/scinai-regains-compliance-nasdaq-minimum-bid-price BiopharmaWatch en 2026-09-21T11:00:00.000Z Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/INSM/fda-priority-review-insmed-arikayce-mac-lung-disease BiopharmaWatch en 2026-09-21T11:00:00.000Z FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 https://www.biopharmawatch.com/news/PGEN/precigen-fda-platform-technology-designation-adenoverse BiopharmaWatch en 2026-09-21T11:00:00.000Z Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-alzheimers-agitation-survey-results BiopharmaWatch en 2026-09-21T11:00:00.000Z Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day https://www.biopharmawatch.com/news/SEER/seer-announces-cfo-transition BiopharmaWatch en 2026-09-21T11:00:00.000Z Seer Announces CFO Transition https://www.biopharmawatch.com/news/MRK/merck-keytruda-qlex-approval-japan BiopharmaWatch en 2026-09-21T10:45:00.000Z Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan https://www.biopharmawatch.com/news/QAI/qscreen-ai-debt-settlement-directors-officers BiopharmaWatch en 2026-09-21T10:14:00.000Z QScreen AI Announces $681,000 Debt Settlement with Directors and Officers https://www.biopharmawatch.com/news/AVTR/avantor-appoints-new-cfo-todd-garner BiopharmaWatch en 2026-09-21T10:05:00.000Z Avantor appoints new Chief Financial Officer https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-21 BiopharmaWatch en 2026-09-21T07:15:28.129Z Biotech Catalysts to Watch: Key Developments Through 2026 https://www.biopharmawatch.com/news/C43/gi-genius-study-improves-adenoma-detection BiopharmaWatch en 2026-09-21T05:07:00.000Z Largest Real-World Study of the GI Genius(TM) Intelligent Endoscopy System Demonstrates Improved Adenoma Detection in Routine Clinical Practice https://www.biopharmawatch.com/news/TLX/telix-itm-merger-radiopharmaceuticals BiopharmaWatch en 2026-09-21T00:55:00.000Z Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse https://www.biopharmawatch.com/news/INCY/specialised-therapeutics-expands-partnership-with-incyte BiopharmaWatch en 2026-09-20T20:00:00.000Z Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia https://www.biopharmawatch.com/news/ASTS/ast-spacemobile-class-action-lawsuit BiopharmaWatch en 2026-09-20T14:00:00.000Z INVESTOR ALERT: AST SpaceMobile, Inc. (NASDAQ: ASTS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit and Should Contact Kessler Topaz Meltzer & Check, LLP https://www.biopharmawatch.com/news/ORBS/eightco-holdings-nasdaq-orbs-meldt-totale-bezittingen-van-ongeveer-usd BiopharmaWatch en 2026-09-20T12:29:00.000Z Eightco Holdings (NASDAQ: ORBS) meldt totale bezittingen van ongeveer USD 380 miljoen, waaronder belangen in OpenAI en Beast Industries, meer dan 16.000 ETH en bijna 302 miljoen WLD-tokens https://www.biopharmawatch.com/news/CUE/cue-biopharma-positive-results-cue-221-phase-2-study BiopharmaWatch en 2026-09-20T10:00:00.000Z Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria https://www.biopharmawatch.com/news/CAH/class-action-lawsuit-cardinal-health-expenses BiopharmaWatch en 2026-09-19T22:32:00.000Z Employment Law Attorneys, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, Filed a Lawsuit Against Cardinal Health 414, LLC, for Alleged Failure to Reimburse Employees' Business Expenses